Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.53 |
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925625 | 0.85 | SPR (0.52) | HSD11B1FPR1HPGDTSHRNPC1 | |
| SCHEMBL1402773 | 0.79 | HSD11B1 (0.57) | HSD11B1FPR1HPGDTSHRNPC1 | |
| SCHEMBL2924918 | 0.79 | P2RX7 (0.44) | HPGDNPC1TP53RAB9AMAPT | |
| SCHEMBL1402919 | 0.78 | HSD11B1 (0.72) | HSD11B1FPR1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1403183 | 0.75 | HSD11B1 (0.58) | HSD11B1FPR1HPGDTSHRNPC1 | |
| SCHEMBL2925940 | 0.71 | FPR1 (0.64) | HSD11B1FPR1HPGDTSHRNPC1 | |
| SCHEMBL2923280 | 0.71 | HPGD (0.40) | HPGDNPC1TP53RAB9AALDH1A1 | |
| SCHEMBL3457843 | 0.70 | ALDH1A1 (0.59) | HSD11B1FPR1HPGDTSHRNPC1 | |
| SCHEMBL2925107 | 0.70 | SPR (0.56) | HSD11B1FPR1HPGDTSHRNPC1 | |
| SCHEMBL20378234 | 0.69 | NR4A3 (0.68) | FPR1HPGDNPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615698-B1 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | claimed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| EP-2239012-A2 | Pharmaceutical use of substituted amides | High Point Pharmaceuticals, LLC (US) | 2010-10-13 | — | — | EP | disclosed |
| EP-1615698-B1 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | disclosed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885FPR1 1280/4885HPGD 28/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | HSD11B1 1/4885FPR1 601/4885HPGD 119/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885FPR1 4067/4885HPGD 84/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885FPR1 4067/4885HPGD 84/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | HSD11B1 1/4885FPR1 601/4885HPGD 119/4885 |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885FPR1 1478/4885HPGD 26/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885FPR1 1280/4885HPGD 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.